NCT00287885View on ClinicalTrials.gov

Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Cervical CancerEndometrial CancerFallopian Tube CancerOvarian CancerPeritoneal Cavity CancerSarcomaVaginal CancerVulvar Cancer
Interventions
DRUG

docetaxel

Three patients will be enrolled and dosed at each level; from dose level 1 of 2.9 mg/m\^2/day up to dose level 6 of 6.4 mg/m\^2/day

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT00287885 - Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer | Biotech Hunter | Biotech Hunter